Since we have demonstrated that CP-bi-apt could specifically bind to PD-L1 that expressed on cancer cells to act as an immune checkpoint inhibitor, multiple injections of CP-bi-apt may not only promote the accumulation of NK cells in tumor sites but also could reduce the influence of PD-L1 up-regulation, thus improving the antitumor effect. The gene discussed is CP; the disease is neoplasm.